Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Sanofi-Aventis: The French company has a "good basis" to expand its OTC presence globally from its current position that is a "little bit overlooked," but generates about $775 million in annual sales, Executive VP for Pharmaceutical Operations Hanspeter Spek says during the firm's July 31 earnings call. Several of Sanofi's brands, including OTC laxative Maalox, are close to reaching global status, he notes. Sanofi reported its fiscal 2008 second-quarter earnings a week after announcing plans to purchase Australia's leading vitamin and mineral supplements firm, Primary Health Care's Symbion Consumer unit, for $521.4 million (1"The Tan Sheet" July 28, 2008, p. 17). Sanofi reported its net sales grew 5.2 percent to 2.73 billion euros ($10.43 billion under July 31 conversion rates) excluding the impact of currency and acquisitions. Sanofi's adjusted net income was flat at $2.73 billion...

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts